Aristeidis Chiotellis

Dr. Aristeidis Chiotellis

National Centre for Scientific Research "Demokritos"
+2
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2023 in Molecules
Verified
Journal Article
Open access
PDF file
KMKonstantina Makrypidi
Konstantina Makrypidi
CKChristos Kiritsis
Christos Kiritsis
IRIoanna Roupa
Ioanna Roupa
STSotiria Triantopoulou
Sotiria Triantopoulou
Antonio SheganiAntonio Shegani
Antonio Shegani
IPIoannis Pirmettis
Ioannis Pirmettis
Τhe Epidermal Growth Factor Receptor tyrosine kinase inhibitor (EGFR-TKI) 6-amino-4-[(3-bromophenyl) amino]quinazoline was derivatized with 6-bromohexanoyl-chloride and coupled with the tridentate chelating agents N-(2-pyridylmethyl) aminoethyl acetic acid (PAMA) and L(+)-cysteine bearing the donor atom set NNO and SNO, respectively. The rhenium precursors ReBr(CO)5 and fac-[NEt4]2[ReBr3(CO)3] were used for the preparation of the Re complexes fac-[Re(NNO)(CO)3] (5a) and fac-[Re(SNO)(CO)3] (7a) which were characterized by NMR and IR spectroscopies. Subsequently, the new potential EGFR inhibitors were labeled with the fac-[99mTc(CO)3]+ core in high yield and radiochemical purity (>90%) by ligand exchange reaction using the fac-[99mTc][Tc(OH2)3(CO)3]+ precursor. The radiolabeled complexes were characterized by comparative HPLC analysis with the analogous rhenium (Re) complexes as references. In vitro studies in the A431 cell lines showed that both ligands and Re complexes inhibit A431 cell growth. Complex 5a demonstrated the highest potency (IC50 = 8.85 ± 2.62 μM) and was further assessed for its capacity to inhibit EGFR autophosphorylation, presenting an IC50 value of 26.11 nM. Biodistribution studies of the 99mTc complexes in healthy mice showed high in vivo stability for both complexes and fast blood and soft tissue clearance with excretion occurring via the hepatobiliary system.

15 September 2021 in Nanomaterials
Verified
Journal Article
Open access
PDF file
AAAdamantia Apostolopoulou
Adamantia Apostolopoulou
Aristeidis ChiotellisAristeidis Chiotellis
Aristeidis Chiotellis
Evangelia-Alexandra SalvanouEvangelia-Alexandra Salvanou
Evangelia-Alexandra Salvanou
KMKonstantina Makrypidi
Konstantina Makrypidi
CTCharalampos Tsoukalas
Charalampos Tsoukalas
PGPenelope Greece
Penelope Greece
Radiolabeled gold nanoparticles (AuNPs) have been widely used for cancer diagnosis and therapy over recent decades. In this study, we focused on the development and in vitro evaluation of four new Au nanoconjugates radiolabeled with technetium-99m (99mTc) via thiol-bearing ligands attached to the NP surface. More specifically, AuNPs of two different sizes (2 nm and 20 nm, referred to as Au(2) and Au(20), respectively) were functionalized with two bifunctional thiol ligands (referred to as L1H and L2H). The shape, size, and morphology of both bare and ligand-bearing AuNPs were characterized by transmission electron microscopy (TEM) and dynamic light scattering (DLS) techniques. In vitro cytotoxicity was assessed in 4T1 murine mammary cancer cells. The AuNPs were successfully radiolabeled with 99mTc-carbonyls at high radiochemical purity (>95%) and showed excellent in vitro stability in competition studies with cysteine and histidine. Moreover, lipophilicity studies were performed in order to determine the lipophilicity of the radiolabeled conjugates, while a hemolysis assay was performed to investigate the biocompatibility of the bare and functionalized AuNPs. We have shown that the functionalized AuNPs developed in this study lead to stable radiolabeled nanoconstructs with the potential to be applied in multimodality imaging or for in vivo tracking of drug-carrying AuNPs.

20 June 2024 in Molecules
Verified
Journal Article
Open access
PDF file
Dimitrios MoianosDimitrios Moianos
Dimitrios Moianos
MMMaria Makri
Maria Makri
GPGeorgia-Myrto Prifti
Georgia-Myrto Prifti
Aristeidis ChiotellisAristeidis Chiotellis
Aristeidis Chiotellis
APAlexandros Pappas
Alexandros Pappas
Grigoris ZoidisGrigoris Zoidis
Grigoris Zoidis
Hepatitis B virus (HBV) remains a global health threat. Ribonuclease H (RNase H), part of the virus polymerase protein, cleaves the pgRNA template during viral genome replication. Inhibition of RNase H activity prevents (+) DNA strand synthesis and results in the accumulation of non-functional genomes, terminating the viral replication cycle. RNase H, though promising, remains an under-explored drug target against HBV. We previously reported the identification of a series of N-hydroxypyridinedione (HPD) imines that effectively inhibit the HBV RNase H. In our effort to further explore the HPD scaffold, we designed, synthesized, and evaluated 18 novel HPD oximes, as well as 4 structurally related minoxidil derivatives and 2 barbituric acid counterparts. The new analogs were docked on the RNase H active site and all proved able to coordinate the two Mg2+ ions in the catalytic site. All of the new HPDs effectively inhibited the viral replication in cell assays exhibiting EC50 values in the low μM range (1.1–7.7 μM) with low cytotoxicity, resulting in selectivity indexes (SI) of up to 92, one of the highest reported to date among HBV RNase H inhibitors. Our findings expand the structure–activity relationships on the HPD scaffold, facilitating the development of even more potent anti-HBV agents.

14 September 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
APAfroditi Papasavva
Afroditi Papasavva
NPNektarios N. Pirmettis
Nektarios N. Pirmettis
Antonio SheganiAntonio Shegani
Antonio Shegani
EPEleni Papadopoulou
Eleni Papadopoulou
CKChristos Kiritsis
Christos Kiritsis
IPIoannis Pirmettis
Ioannis Pirmettis
Background: The accurate diagnosis of bacterial infections remains a critical challenge in clinical practice. Traditional imaging modalities like computed tomography (CT) and magnetic resonance imaging (MRI) often fail to distinguish bacterial infections from sterile inflammation. Nuclear medicine, such as technetium-99m (99mTc) radiopharmaceuticals, offers a promising alternative due to its ideal characteristics. Methods: This study explores the development of [2 + 1] mixed-ligand 99mTc-labeled ciprofloxacin dithiocarbamate (Cip-DTC) complexes combined with various phosphine ligands, including triphenylphosphine (PPh3), tris(4-methoxyphenyl)phosphine (TMPP), methyl(diphenyl)phosphine (MePPh2), dimethylphenylphosphine (DMPP), and 1,3,5-triaza-7-phosphaadamantane (ADAP). The characterization of 99mTc-complexes was conducted using rhenium analogs as structural models to ensure similar coordination. Results: Stability studies demonstrated the high integrity (97–98%) of the complexes under various conditions, including cysteine and histidine challenges. Lipophilicity studies indicated that complexes with higher logD7.4 values (1.6–2.7) exhibited enhanced tissue penetration and prolonged circulation. Biodistribution studies in Swiss Albino mice with induced infections and aseptic inflammation revealed distinct patterns. Specifically, the complex fac-[99mTc(CO)3(Cip-DTC)(PPh3)] (2′) showed high infected/normal muscle ratios (4.62 at 120 min), while the complex fac-[99mTc(CO)3(Cip-DTC)(TMPP)] (3′) demonstrated delayed but effective targeting (infected/normal muscle ratio of 3.32 at 120 min). Conclusions: These findings highlight the potential of 99mTc-labeled complexes as effective radiopharmaceuticals for the differential diagnosis of bacterial infections, advancing nuclear medicine diagnostics. Future studies will focus on optimizing molecular weight, lipophilicity, and stability to further enhance the diagnostic specificity and clinical utility of these radiopharmaceuticals.

1 January 2022 in Bioinorganic Chemistry and Applications
Verified
Journal Article
Open access
PDF file
IRIoanna Roupa
Ioanna Roupa
CFCharalampos Flampouraris
Charalampos Flampouraris
Antonio SheganiAntonio Shegani
Antonio Shegani
MIMyrto Ischyropoulou
Myrto Ischyropoulou
KMKonstantina Makrypidi
Konstantina Makrypidi
Aristeidis ChiotellisAristeidis Chiotellis
Aristeidis Chiotellis
In the pursuit of hydrophilic model fac‐[Re(CO)3]+ complexes for (radio) pharmaceutical applications, six novel [2 + 1] mixed‐ligand complexes of the general type fac‐[Re(CO)3(bid)P] were synthesized and characterized, where bid is a bidentate ligand bearing either (N, O) or (S, S′) donor atom sets and P is the hydrophilic phosphine 1,3,5‐triaza‐7‐phosphoadamantane (PTA) or its macrocyclic homologue 1,4,7‐triaza‐9‐phosphatricyclo[5.3.2.1]tridecane (CAP). The (N, O) ligands used in this study were picolinic and quinaldic acid, while the (S, S′) ligand was diethyldithiocarbamate. The complexes were synthesized in generally high yields and purity and the characterization was performed by spectroscopic methods, IR, NMR, and elemental analysis. Detailed X‐ray crystallographic study of molecular packing by using Hirshfeld analysis tools revealed a plethora of intermolecular interactions such as hydrogen bond, π⋯π, C‐H⋯π, and carbonyl‐carbonyl interactions. To our knowledge, the CAP complexes reported herein are the first example of [2 + 1] mixed‐ligand fac‐[Re(CO)3]+ complexes with CAP. The new complexes might have the potential to serve as platforms for the design of target‐specific complexes with favorable pharmacokinetics.

16 September 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
STSotiria Triantopoulou
Sotiria Triantopoulou
IRIoanna Roupa
Ioanna Roupa
Antonio SheganiAntonio Shegani
Antonio Shegani
NPNektarios N. Pirmettis
Nektarios N. Pirmettis
GTGeorgia I. Terzoudi
Georgia I. Terzoudi
MPMaria Paravatou-Petsota
Maria Paravatou-Petsota
Background/Objectives: Epidermal growth factor receptor (EGFR) plays a vital role in cell proliferation and survival, with its overexpression linked to various malignancies, including non-small cell lung cancer (NSCLC). Although EGFR tyrosine kinase inhibitors (TKIs) are a key therapeutic strategy, acquired resistance and relapse remain challenges. This study aimed to synthesize and evaluate novel rhenium-based complexes incorporating EGFR TKIs to enhance anticancer efficacy, particularly in radiosensitization. Methods: We synthesized a rhenium tricarbonyl complex (Complex 2) and its 99mTc analog (Complex 2’) by incorporating triphenylphosphine instead of bromine as the monodentate ligand and PF6− as the counter-ion, resulting in a positively charged compound that forms cationic structures. Cytotoxicity and EGFR inhibition were evaluated in A431 cells overexpressing EGFR using MTT assays, Western blotting, and flow cytometry. Radiosensitization was tested through MTT and clonogenic assays. The 99mTc complex’s radiochemical yield, stability, and lipophilicity were also assessed. Results: Complex 2 exhibited significant cytotoxicity with an IC50 of 2.6 μM and EGFR phosphorylation inhibition with an IC50 of 130.6 nM. Both complex 1 and 2 induced G0/G1 cell cycle arrest, with Complex 2 causing apoptosis. Radiosensitization was observed at doses above 2 Gy. Complex 2’ demonstrated high stability and favorable lipophilicity (LogD7.4 3.2), showing 12% cellular uptake after 30 min. Conclusions: Complexes 2 and 2’ show promise as dual-function anticancer agents, offering EGFR inhibition, apoptosis induction, and radiosensitization. Their potential as radiopharmaceuticals warrants further in-depth investigation in preclinical models.